STAT3 and systemic sclerosis: In the current study, the ARβ blocker, propranolol, the p38 inhibitor, SB203580, and STAT3 inhibitor, S31-201 inhibited the NE-induced IL-6 production and fibrosis in SSc fibroblasts in vitro, suggesting that ARβ blocker, p38 and/or STAT3 inhibitor therapy can be an alternative treatment for skin sclerosis in patients with SSc45.